It's important to understand that a news segment isn't a
It's important to understand that a news segment isn't a press release. A company has complete control over a press release. In a news segment, it has control of one thing only: What comes out of its representative's mouth. And even that can sometimes be messed with through editing and the like.
Media is free publicity, but it comes with a risk. Like some fool of a mother talking about her daughter's 'marijuana addiction.' But it comes with a positive, too: It 'declares' that the company is of sufficient interest to merit media attention. It implicitly bestows bona fides. It credentializes.
Press releases are that reality turned on its head. The company has complete control, and control is good! But so is third-party validation (even if it's only implied validation), and you don't get that with a press release.
I don't think that interview hurt us. At this point, the game is all about 'creating impressions,' about getting the brand name(s) out there. The interview did that. It got the ball rolling, and that's the name of the game at this point.
6
Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nvidia Invests $500 Million in Wayve Nvidia, known for its advanced AI technologies, is in discussions to invest a substantial $500 million into the U.K.-based autonomous driving startup Wayve. This move marks a significant step for Nvidia as it seeks to deepen its involvement in the rapidly evolving artificial intelligence sector. Strategic Importance of the Investment...
Continue Reading
Elevating Leadership at Vortex Companies Vortex Companies, known for its rapid growth in the trenchless infrastructure rehabilitation sector, has recently made significant leadership changes with the promotions of Jonathan Thomas and Connor Mathis. Thomas steps into the role of Senior Regional Vice President for the Coastal Region, while Mathis ascends to Regional Vice...
Continue Reading
Scilex Holding Company’s FDA Milestone with ELYXYB Scilex Holding Company, based in Palo Alto, California, has gained significant recognition with the U.S. FDA's acknowledgment of their Supplemental New Drug Application (SNDA) for ELYXYB. This marks a substantial step forward for the company, which is dedicated to creating and advancing non-opioid pain management...
Continue Reading
Advanced Proteins in the Spotlight Bio-Techne’s latest move is creating some serious buzz in the life sciences scene. They're not just talking the talk but walking the walk by expanding their R&D Systems AI-Engineered Designer Protein portfolio. What's the big news? They've engineered heat-stable and hyperactive proteins that promise to shake up fibroblast growth factor...
Continue Reading
Groundbreaking Advances in Surgical Infection Prevention PolyPid Ltd. has made headlines recently, unveiling remarkable topline results from their pivotal SHIELD II Phase 3 trial. This innovative study showcased D-PLEX100, a major breakthrough in preventing surgical site infections (SSIs), showing statistically significant reductions in both primary and secondary...
Continue Reading